Immune checkpoint inhibitors plus anti-angiogenesis in patients with resected high-risk hepatitis B virus-associated hepatocellular carcinoma

Table 3 Adverse events of any grade occurring in ≥ 15% of patients according to Common Terminology Criteria for Adverse Events 5.0, n (%)

Adverse events	All grades	1	2	3-4
Hypertension	20 (66.7)	3 (10.0)	7 (23.3)	10 (33.3)
Platelet count decreased	14 (46.7)	6 (20.0)	5 (16.7)	3 (10.0)
Aspartate aminotransaminase increased	12 (40.0)	4 (13.3)	4 (13.3)	4 (13.3)
Total bilirubin increased	11 (36.7)	4 (13.3)	4 (13.3)	3 (10.0)
Proteinuria	11 (36.7)	2 (6.7)	8 (26.7)	1 (3.3)
Pain	10 (33.3)	4 (13.3)	5 (16.7)	1 (3.3)
Neutrophil count decreased	9 (30.0)	0	7 (23.3)	2 (6.7)
Alanine aminotransferase increased	9 (30.0)	4 (13.3)	4 (13.3)	1 (3.3)
Gamma glutamyl transferase increased	8 (26.7)	1 (3.3)	2 (6.7)	5 (16.7)
Diarrhea	7 (23.3)	3 (10.0)	3 (10.0)	1 (3.3)
Hypothyroidism	7 (23.3)	3 (10.0)	4 (13.3)	0
Hand-foot syndrome	7 (23.3)	1 (3.3)	4 (13.3)	2 (6.7)
Alkaline phosphatase increased	5 (16.7)	4 (13.3)	1 (3.3)	0
Hyperthyroidism	5 (16.7)	2 (6.7)	3 (10.0)	0
Rash	5 (16.7)	3 (10.0)	1 (3.3)	1 (3.3)
Weight loss	5 (16.7)	2 (6.7)	2 (6.7)	1 (3.3)